No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
‘Blow’ to Australia’s Alzheimer’s Patients – TGA Rejects Eisai’s Leqembi® (Lecanemab) Due To Safety & Efficacy Concerns
On 16 October 2024, Australia's Therapeutic Goods Administration (TGA) reported its decision not to register Leqembi® (lecanemab) for the treatment of patients with mild Alzheimer's dementia (early Alzheimer’s disease) and mild cognitive impairment (MCI) due to...